Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) and Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, announced the receipt of initial orders for Vasogen's Celacade(TM) System in Germany. Celacade, a first-in-class therapy, is the only CE Mark approved product that specifically targets the destructive chronic inflammation underlying the development and progression of chronic heart failure. Under the CE Mark, Celacade can be marketed in the 27 countries that comprise the European Union and is indicated in the EU for the treatment of New York Heart Association (NYHA) Class II patients and NYHA Class II, III, & IV heart failure patients who do not...

Want to see the full article?

• Purchase this article for only $3.00